CeriBell (NASDAQ:CBLL - Get Free Report) had its target price raised by equities research analysts at Canaccord Genuity Group from $30.00 to $31.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Canaccord Genuity Group's price target suggests a potential upside of 11.19% from the company's previous close.
Several other equities analysts also recently commented on CBLL. JPMorgan Chase & Co. initiated coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued an "overweight" rating and a $32.00 price target for the company. TD Cowen began coverage on CeriBell in a report on Tuesday, November 5th. They issued a "buy" rating and a $31.00 target price for the company. Bank of America began coverage on shares of CeriBell in a research note on Tuesday, November 5th. They set a "buy" rating and a $32.00 target price for the company. William Blair initiated coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an "outperform" rating on the stock. Finally, Canaccord Genuity Group began coverage on shares of CeriBell in a research note on Tuesday, November 5th. They set a "buy" rating and a $30.00 price target on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $31.20.
Check Out Our Latest Research Report on CeriBell
CeriBell Stock Down 3.4 %
Shares of CBLL traded down $0.97 during midday trading on Wednesday, reaching $27.88. The company had a trading volume of 204,238 shares, compared to its average volume of 236,871. CeriBell has a 1-year low of $23.00 and a 1-year high of $29.53.
About CeriBell
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Stories
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
